The effect of hypertension on the course and severity of psoriasis

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Hypertension is one of the significant comorbid diseases in psoriatic patients that have an important impact on the quality of life of patients. Early studies and literature reviews mostly considered psoriasis as an inducing factor in the development of many comorbidities, including cardiovascular diseases in general, and also highlighted the influence of psoriasis on the severity and course of comorbid conditions. In this review, special attention is paid to hypertension as an independent risk factor for the onset of psoriasis, pathogenetic mechanisms indicating the possibility of psoriasis induction by existing hypertension are presented, as well as information on how hypertension aggravates the course, clinical manifestations, severity and the possibility of therapy of the underlying disease.

Full Text

Restricted Access

About the authors

M. S. Muminova

Peoples’ Friendship University of Russia

Author for correspondence.
Email: marykor@bk.ru
ORCID iD: 0000-0002-8620-6266
Russian Federation, Moscow

O. V. Zhukova

Peoples’ Friendship University of Russia

Email: marykor@bk.ru
ORCID iD: 0000-0001-5723-6573

Doctor of Medical Sciences, Professor

Russian Federation, Moscow

E. V. Dvoryankova

Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences

Email: marykor@bk.ru
ORCID iD: 0000-0002-2458-419X

Doctor of Medical Sciences

Russian Federation, Moscow

I. M. Korsunskaya

Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences

Email: marykor@bk.ru
ORCID iD: 0000-0002-6583-0318

Doctor of Medical Sciences, Professor

Russian Federation, Moscow

References

  1. Phan C., Sigal M.L., Lhafa M. et al. Metabolic comorbidities and hypertension in psoriasis patients in France. Comparisons with French national databases. Ann Dermatol Venereol. 2016; 143 (4): 264–74. doi: 10.1016/j.annder.2015.06.024
  2. Cohen A.D., Weitzman D., Dreiher J. Psoriasis and hypertension: a case-control study. Acta Derm Venereol. 2010; 90 (1): 23–6. doi: 10.2340/00015555-0741
  3. Qureshi A.A., Choi H.K., Setty A.R. et al. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol. 2009; 145 (4): 379–82. doi: 10.1001/archdermatol.2009.48
  4. Armstrong A.W., Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020; 323 (19): 1945–60. doi: 10.1001/jama.2020.4006
  5. Daugaard C., Iversen L., Hjuler K.F. Comorbidity in Adult Psoriasis: Considerations for the Clinician. Psoriasis (Auckl). 2022; 12: 139–50. doi: 10.2147/PTT.S328572
  6. Liu L., Cui S., Liu M. et al. Psoriasis Increased the Risk of Adverse Cardiovascular Outcomes: A New Systematic Review and Meta-Analysis of Cohort Study. Front Cardiovasc Med. 2022; 9: 829709. doi: 10.3389/fcvm.2022.829709. Erratum in: Front Cardiovasc Med. 2022; 9: 929149.
  7. Laws P.M., Warren R.B. Psoriasis and comorbidities. In: Advances in Psoriasis. Weinberg J.M. and Lebwohl M. (eds). Springer, Cham, 2021; pp. 363–97.
  8. Setty A.R., Curhan G., Choi H.K. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med. 2007; 167 (15): 1670–5. doi: 10.1001/archinte.167.15.1670
  9. Mills K.T., Stefanescu A., He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020; 16 (4): 223–37. doi: 10.1038/s41581-019-0244-2
  10. Takeshita J., Wang S., Shin D.B. et al. Effect of psoriasis severity on hypertension control: a population-based study in the United Kingdom. JAMA Dermatol. 2015; 151 (2): 161–9. doi: 10.1001/jamadermatol.2014.2094
  11. Masson W., Lobo M., Molinero G. Psoriasis and Cardiovascular Risk: A Comprehensive Review. Adv Ther. 2020; 37 (5): 2017–33. doi: 10.1007/s12325-020-01346-6
  12. Karpińska-Mirecka A., Bartosińska J., Krasowska D. The Impact of Hypertension, Diabetes, Lipid Disorders, Overweight/Obesity and Nicotine Dependence on Health-Related Quality of Life and Psoriasis Severity in Psoriatic Patients Receiving Systemic Conventional and Biological Treatment. Int J Environ Res Public Health. 2021; 18 (24): 13167. doi: 10.3390/ijerph182413167
  13. Chiu H.Y., Chang W.L., Shiu M.N. et al. Psoriasis is associated with a greater risk for cardiovascular procedure and surgery in patients with hypertension: A nationwide cohort study. J Dermatol. 2018; 45 (12): 1381–8. doi: 10.1111/1346-8138.14654
  14. Wu S., Han J., Li W.Q. et al. Hypertension, antihypertensive medication use, and risk of psoriasis. JAMA Dermatol. 2014; 150 (9): 957–63. doi: 10.1001/jamadermatol.2013.9957
  15. Kim H.N., Han K., Song S.W. et al. Hypertension and risk of psoriasis incidence: An 11-year nationwide population-based cohort study. PLoS One. 2018; 13 (8): e0202854. doi: 10.1371/journal.pone.0202854
  16. El Ghareeb M.I., Khater M.H., Fakhr A. et al. Risk and severity of psoriasis vulgaris in relation to angiotensin II type 1 receptor gene polymorphism and metabolic syndrome. Clin Cosmet Investig Dermatol. 2019; 12: 683–90. doi: 10.2147/CCID.S212781
  17. Ramezani M., Zavattaro E., Sadeghi M. Angiotensin-converting enzyme gene insertion/deletion polymorphism and susceptibility to psoriasis: a systematic review and meta-analysis. BMC Med Genet. 2020; 21 (1): 8. doi: 10.1186/s12881-019-0943-3
  18. Weger W., Hofer A., Wolf P. et al. The angiotensin-converting enzyme insertion/deletion and the endothelin -134 3A/4A gene polymorphisms in patients with chronic plaque psoriasis. Exp Dermatol. 2007; 16 (12): 993–8. doi: 10.1111/j.1600-0625.2007.00620.x
  19. Veletza S., Karpouzis A., Giassakis G. et al. Assessment of insertion/deletion polymorphism of the angiotensin converting enzyme gene in psoriasis. J Dermatol Sci. 2008; 49 (1): 85–7. doi: 10.1016/j.jdermsci.2007.08.005
  20. Lamba G., Palaniswamy C., Singh T. et al. Psoriasis induced by losartan therapy: a case report and review of the literature. Am J Ther. 2011; 18 (3): e78–80. doi: 10.1097/MJT.0b013e3181c6c0c2
  21. Silva I.M.S., Assersen K.B., Willadsen N.N. et al. The role of the renin-angiotensin system in skin physiology and pathophysiology. Exp Dermatol. 2020; 29 (9): 891–901. doi: 10.1111/exd.14159
  22. Song G.G., Bae S.C., Kim J.H. et al. The angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to rheumatoid arthritis, vitiligo and psoriasis: A meta-analysis. J Renin Angiotensin Aldosterone Syst. 2015; 16 (1): 195–202. doi: 10.1177/1470320313478285
  23. Purzycka-Bohdan D., Kisielnicka A., Bohdan M. et al. Analysis of the Potential Genetic Links between Psoriasis and Cardiovascular Risk Factors. Int J Mol Sci. 2021; 22 (16): 9063. doi: 10.3390/ijms22169063
  24. Armesto S., Coto-Segura P., Osuna C.G. et al. Psoriasis and hypertension: a case-control study. J Eur Acad Dermatol Venereol. 2012; 26 (6): 785–8. doi: 10.1111/j.1468-3083.2011.04108.x
  25. Gerdes S., Zahl V.A., Knopf H. et al. Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis. Br J Dermatol. 2008; 159 (5): 1116–23. doi: 10.1111/j.1365-2133.2008.08786.x
  26. Müller G., Lübow C., Weindl G. Lysosomotropic beta blockers induce oxidative stress and IL23A production in Langerhans cells. Autophagy. 2020; 16 (8): 1380–95. doi: 10.1080/15548627.2019.1686728
  27. Kim G.K., Del Rosso J.Q. Drug-provoked psoriasis: is it drug induced or drug aggravated?: understanding pathophysiology and clinical relevance. J Clin Aesthet Dermatol. 2010; 3 (1): 32–8.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 Russkiy Vrach Publishing House